IVIG Market Growth Analysis and Industry Revenue By Top Key Pioneers Baxter International, CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma, LFB group, Biotest AG, China Biologics Products, BDI Pharma, Bayer Healthcare

IVIG market is driven by the increase in prevalence of chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia, and rise in use of immunoglobulins to treat GuillainBarre syndrome, inflammatory myopathies, specific antibody deficiency, and others. Further, the increase in approval of intravenous immunoglobulin (IVIG) drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin.

Download [PDF] Report Sample @ https://www.alliedmarketresearch.com/request-sample/325

IVIG market (Intravenous Immunoglobulin Market) was valued at $7,861 million, and is expected to reach $12,632 million by 2022, supported by a CAGR of 7.1%.

Key factors driving the market growth include approvals for IVIG therapy from FDA, EMA, and government, increase in awareness about IVIG treatment, rise in incidence of antibody deficiency diseases & hemophilic patients, and emergence of technologically advanced IVIG products. However, high cost products, side effects associated with its treatment, and stringent regulations restrict new product launch and hamper the IVIG market growth.

The hypogammaglobulinemia, CIDP, and immunodeficiency diseases segments together accounted for more than half market share in 2015, owing to high efficacy of IVIG treatment. Myasthenia gravis is the fastest growing segment, which is projected to grow at a CAGR of 10%.

Geographically, North America accounted for majority of the share, accounting for about 50% in 2015, and is expected to maintain its lead. This was attributed to the increased adoption of IVIG treatments, growth in incidence of immunodeficiency diseases, and high healthcare expenditure. However, regulatory framework concerns and limited IVIG products supply in North America adversely affect the market growth.

LAMEA is projected to grow at the highest CAGR of 10%, owing to the improving healthcare infrastructures and increasing expenditures in emerging markets to overcome the unmet medical needs in underdeveloped countries. Latin America led the market, with more than half of the LAMEA IVIG market share in 2015.

Key findings of IVIG Market:

- Specific antibody deficiency is the second fastest growing application in IVIG market, growing at a CAGR of 9% over the forecast period.

- The global IVIG market size accounted for 142 tons, in terms of volume, in 2015, and is expected to reach 236 tons by 2022, growing at a CAGR of 7%.

- Europe, the second fastest growing region, is expected to reach $3,000 million, in terms of value, by 2022.

Key players in the IVIG market focus on expanding their business operations in emerging countries, with new product launches as a preferred strategy. Leading companies profiled in this report include

- Baxter International Inc.,
- CSL Ltd.,
- Grifols S.A,
- Octapharma AG,
- Kedrion Biopharma Inc.,
- LFB group,
- Biotest AG,
- China Biologics Products, Inc.,
- BDI Pharma Inc., and Bayer Healthcare.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/325

List of Tables

TABLE 1. IVIG PRODUCTS COMMERCIALIZED IN MARKET
TABLE 2. USFDA INDICATIONS FOR IVIG
TABLE 3. EMA APPROVED INDICATIONS FOR IVIG
TABLE 4. IGG SUBCLASS
TABLE 5. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 6. DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
TABLE 7. CLINICAL TRIALS FOR IVIG (2011-2014)
TABLE 8. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022,($MILLION)
TABLE 9. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022, (TON)
TABLE 10. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 11. HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 12. CIDP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 13. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
TABLE 14. IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 15. MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 16. MMN IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 17. ITP TREATMENT OPTIONS
TABLE 18. ITP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 19. INFLAMMATORY MYOPATHIES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 20. SAD IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 21. GBS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 22. OTHER IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 23. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, ($MILLION)
TABLE 24. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, (TON)
TABLE 25. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 26. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 27. U.S. IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 28. CANADA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 29. MEXICO IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 30. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 31. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 32. U.K. IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 33. FRANCE IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 34. GERMANY IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 35. ITALY IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 36. AUSTRIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 37. RUSSIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 38. OTHER IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 39. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 40. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 41. AUSTRALIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 42. CHINA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 43. JAPAN IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 44. INDIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 45. OTHER IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 46. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 47. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 48. LATIN AMERICA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 49. AFRICA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 50. MIDDLE EAST IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 51. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 52. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 53. CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT
TABLE 54. CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 55. GRIFOLS S.A SNAPSHOT
TABLE 56. GRIFOLS S.A OPERATING SEGEMENTS
TABLE 57. KEDRION INC. SNAPSHOT
TABLE 58. KEDRION BIOPHARMA OPERATING SEGMENTS
TABLE 59. CSL BEHRING SNAPSHOT
TABLE 60. CSL BEHRING OPERATING SEGMENTS
TABLE 61. BDI PHARMA INC SNAPSHOT
TABLE 62. BDIPHARMA OPERATING SEGMENTS
TABLE 63. BAYER HEALTHCARE COMPANY SNAPSHOT

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/intravenous-immunoglobulin-IVIG-market.html

About Us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.